Biodesix (NASDAQ:BDSX) Posts Earnings Results, Beats Estimates By $0.32 EPS

Biodesix (NASDAQ:BDSX) posted its quarterly earnings data on Monday. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.32, Zacks reports. Biodesix had a negative return on equity of 1,760.83% and a negative net margin of 39.85%.The company had revenue of $25.56 million for the quarter, compared to analyst estimates of $23.12 million.

Here are the key takeaways from Biodesix’s conference call:

• Biodesix reported first-quarter revenue of $25.6 million (up 42% YoY) and raised 2026 guidance to $108–$114 million, implying ~25% growth at the midpoint versus 2025.
• Gross margin expanded to 84% GAAP (82% ex one‑time benefit), adjusted EBITDA loss improved 35% to a $4.1 million loss and net loss narrowed 30%, signaling continued operating leverage and progress toward sustained profitability.
• Diagnostic momentum includes ~17,800 tests in Q1 (up 29% YoY) with primary care now ~15% of volumes and a field team of ~100 reps (adding ~6 reps/quarter); management expects volume-driven growth but is reinvesting in commercial capacity, which raises near‑term operating expense.
• Development services revenue nearly doubled to $3.3 million and the company exited the quarter with about $10.4 million in contracted backlog, reflecting sustained biopharma demand and multi‑omic differentiation.

Biodesix Stock Performance

Shares of Biodesix stock opened at $13.68 on Tuesday. The stock has a market capitalization of $138.29 million, a PE ratio of -2.85 and a beta of 0.43. Biodesix has a 52 week low of $3.44 and a 52 week high of $20.21. The stock has a 50 day moving average price of $14.39 and a two-hundred day moving average price of $10.36.

Insiders Place Their Bets

In other Biodesix news, CEO Scott Hutton sold 3,559 shares of the firm’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $10.08, for a total value of $35,874.72. Following the transaction, the chief executive officer directly owned 45,413 shares of the company’s stock, valued at approximately $457,763.04. This trade represents a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 9,052 shares of company stock worth $100,227 in the last 90 days. Corporate insiders own 23.20% of the company’s stock.

Institutional Investors Weigh In On Biodesix

A number of institutional investors and hedge funds have recently made changes to their positions in BDSX. XTX Topco Ltd lifted its position in Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Cetera Investment Advisers bought a new stake in Biodesix during the 4th quarter worth approximately $68,000. DRW Securities LLC purchased a new stake in shares of Biodesix in the fourth quarter worth approximately $105,000. Millennium Management LLC purchased a new stake in shares of Biodesix in the third quarter worth approximately $113,000. Finally, State Street Corp lifted its holdings in shares of Biodesix by 15.6% in the fourth quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after purchasing an additional 2,400 shares in the last quarter. Institutional investors and hedge funds own 20.96% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BDSX. William Blair upgraded shares of Biodesix from a “market perform” rating to an “outperform” rating in a research report on Friday, February 27th. Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price target on shares of Biodesix in a report on Tuesday, February 17th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.50.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.